OncLive SOSS

Authors

Deni Deasy Boekell

Latest:

The Evolving Use of White Bagging in Oncology

Channel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers.

Denise A. Yardley, MD

Latest:

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Denise A. Yardley, MD, Sarah Cannon

Denise A. Yardley, MD, Sarah Cannon Research Institute

Latest:

No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Denise R. Aberle, MD

Latest:

Dr. Aberle on Novel Approaches to Screening for Lung Cancer

Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.

Denise Soltow Hershey, PhD, RN, FNP-BC

Latest:

Improving Glycemic Control in Individuals With Cancer and Diabetes

It is estimated that 8%-18% of all cancer patients will have preexisting diabetes at the time they are diagnosed with cancer.

Denise Yardley, MD, Tennessee Oncology

Latest:

Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral Metastases

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Dennie V. Jones, Jr, M

Latest:

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

Dennis Bittner, PhD

Latest:

Liquid Biopsy Technology Grows More Varied and Potentially More Useful in NSCLC

The definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.

Dennis C. Shrieve, MD, PhD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Dennis D. Hickstein, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Dennis Fitzgerald, MD

Latest:

Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast Cancer

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.

Dennis J. Slamon, MD, PhD

Latest:

Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer

Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Dennis R. Scribner, MD

Latest:

Dr. Scribner on the Role of Chemotherapy in Ovarian Cancer

Dennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.

Dennise Geiger, RN

Latest:

Dennise Geiger Discusses Telephone Triage in Cancer Care

Dennise Geiger, RN, Regional Cancer Care Associates, Central Jersey Division, discusses difficulties nurses face when using telephone triage, and the plan that was developed to better streamline the process.Â

denosumab-wins-drug-award

Latest:

Denosumab Wins Drug Award

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

Derek SantAngelo, PhD

Latest:

Dr. Sant'Angelo Explains Immunology Basics for Oncologists

Derek Sant'Angelo, PhD, Division Chief, Developmental Biology, Robert Wood Johnson Medical School, Dept. of Pediatrics, discusses what medical oncologists need to understand about immunology.

Deukwoo Kwon, PhD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Devalingam Mahalingam, MD, PhD

Latest:

Autophagy Modulation May Be a Novel Approach to Treatment of Advanced Cancers

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.